APA Citatie

Jo, J., Yoon, D. H., Kim, S., Park, J. S., Park, C., Huh, J., . . . Suh, C. (2012). Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis.

Chicago Style citaat

Jo, Jae-Cheol, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Chan-Sik Park, Jooryung Huh, Sang-Wook Lee, Jin-Sook Ryu, en Cheolwon Suh. Yttrium-90 Ibritumomab Tiuxetan Plus Busulfan, Cyclophosphamide, and Etoposide (BuCyE) Versus BuCyE Alone As a Conditioning Regimen for Non-Hodgkin Lymphoma. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis, 2012.

MLA citatie

Jo, Jae-Cheol, et al. Yttrium-90 Ibritumomab Tiuxetan Plus Busulfan, Cyclophosphamide, and Etoposide (BuCyE) Versus BuCyE Alone As a Conditioning Regimen for Non-Hodgkin Lymphoma. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis, 2012.